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Introduction
The tumor suppressor proteins 53BP1 and BRCA1 have 
emerged as key regulators of the choice between DNA double-
strand break (DSB) repair mechanisms.1-5 Recruitment of BRCA1 
to DSBs promotes the DNA end resection that is necessary for 
homologous recombination (HR),6 a mechanism that repairs 
DNA with great fidelity using sister chromatids as templates for 
recombination.7 In contrast, 53BP1 binding to DSBs inhibits end 
resection and facilitates non-homologous end joining (NHEJ), 
which is considered an error-prone mechanism of DNA repair.
A number of studies have addressed the functional relationship 
between 53BP1 and BRCA1 during the cell cycle in an attempt 
to understand the contribution of HR and NHEJ to the repair 
of DNA DSBs at different phases of the cell cycle.8-10 Some stud-
ies proposed that HR is the preferred mechanism of DSB repair 
during S and G
2
 phases of the cell cycle, while NHEJ functions 
throughout the cell cycle, being dominant in G
1
. In HR-deficient 
cells, NHEJ can repair up to 85% of DSBs in G
2
, supporting 
the notion that these 2 pathways compete for repair substrate.11-14 
Initial studies showed high levels of BRCA1 in exponentially 
growing cells, which decreased dramatically upon growth fac-




,15-17 and a progressive upregu-
lation of BRCA1 and formation of BRCA1/CtIP/MRN DNA 
repair complexes as cells re-entered the cell cycle.18 These data 
suggested that the regulation of BRCA1 levels during the cell 
cycle could be responsible for favoring 53BP1-dependent NHEJ 
during G
1
 and HR during S and G
2
 phases of the cell cycle.
However, recent studies using time-lapse microscopy and 
fluorescent reporters to monitor DSBs in asynchronous cycling 
cells have challenged this notion. One study confirmed that 
early in G
1
, cells repair DSBs exclusively by NHEJ.19 However, 
cells damaged toward the end of G
1
 activate HR, which is most 
active coinciding with the highest levels of replication during S 
phase. Cells damaged during late S and G
2
 exhibit both HR and 
NHEJ. These findings revealed a relationship between the lev-
els of active replication and HR and indicated that NHEJ is the 




 phases. Another 
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BRCA1 and 53Bp1 play decisive roles in the choice of DNA double-strand break repair mechanisms. BRCA1 promotes 
DNA end resection and homologous recombination (HR) during S/G2 phases of the cell cycle, while 53Bp1 inhibits end 
resection and facilitates non-homologous end-joining (NHeJ), primarily during G1. this competitive relationship is critical 
for genome integrity during cell division. However, their relationship in the many cells in our body that are not cycling is 
unknown. We discovered profound differences in 53Bp1 and BRCA1 regulation between cycling and non-cycling cells. 
Cellular growth arrest results in transcriptional downregulation of BRCA1 and activation of cathepsin-L (CtSL)-mediated 
degradation of 53Bp1. Accordingly, growth-arrested cells do not form BRCA1 or 53Bp1 ionizing radiation-induced foci 
(IRIF). Interestingly, cell cycle re-entry reverts this scenario, with upregulation of BRCA1, downregulation of CtSL, sta-
bilization of 53Bp1, and 53Bp1 IRIF formation throughout the cycle, indicating that BRCA1 and 53Bp1 are important in 
replicating cells and dispensable in non-cycling cells. We show that CtSL-mediated degradation of 53Bp1, previously 
associated with aggressive breast cancers, is an endogenous mechanism of non-cycling cells to balance NHeJ (53Bp1) 
and HR (BRCA1). Breast cancer cells exploit this mechanism to ensure genome stability and viability, providing an oppor-
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study has provided mechanistic insights about the functional 
antagonistic relationship between these 2 DNA repair pathways 
in cycling cells.20 The model proposed is somewhat different 
from the previous study, showing that BRCA1 in complex with 
CtIP promotes end resection of the DSB, while antagonizing the 
binding of a complex formed by 53BP1 and Rif1 to the break 
during S and G
2
 phases of the cell cycle. Inhibition of 53BP1/
Rif1 recruitment requires CDK-mediated phosphorylation of 
CtIP. In turn, recruitment of the 53BP1/Rif1 complex, which 
requires ATM-dependent phosphorylation of 53BP1 N terminus, 
inhibits the recruitment of the BRCA1/CtIP complex during G
1
. 
This study proposed a cell cycle-regulated circuit whereby the 
recruitment of BRCA1/CtIP or 53BP1/Rif1 complexes regulate 
DNA DSB repair pathway choice to ensure predominance of 
NHEJ during G
1
 and of HR during S and G
2
 phases of the cell 
cycle. Importantly, the latter study reported that the global levels 
of BRCA1 do not change during the cell cycle.20
Although the specific contributions of BRCA1 and 53BP1 to 
DNA repair mechanisms during the cell cycle remain contro-
versial, it is well accepted that a balance between BRCA1 and 
53BP1 is important for the maintenance of genome integrity. 
Accordingly, different lines of evidence have associated loss of 
either of these proteins with accumulation of DNA damage and 
genomic instability and with increased cancer incidence.21-25 
Interestingly, 53BP1 proficiency seems to play a major role in the 
profound genomic instability that results from BRCA1 deficiency. 
Recent groundbreaking studies demonstrated that loss of 53BP1 
is synthetically viable with the loss of BRCA1.1-5 Loss of 53BP1 
in the context of BRCA1 deficiency allows end resection and 
partially rescues HR defects. Interestingly, loss of 53BP1 rescued 
embryonic lethality in BRCA1-deficient mice (BRCA1Δ11/ Δ11). 
Furthermore, reduced levels of 53BP1 were observed in breast 
cancers with the poorest prognosis, such as BRCA1-mutated and 
triple-negative (TNBC). Overall, these studies suggest that loss 
of 53BP1 contributes to tumor progression, especially in those 
tumors that present HR deficiencies.
The mechanisms responsible for regulating 53BP1 protein 
levels in normal cells or downregulating 53BP1 in tumor cells 
remain poorly understood. Our previous studies identified one 
mechanism modulating the levels of 53BP1 protein in mam-
malian cells. Initially, we found that depletion of the structural 
nuclear proteins A-type lamins activate the degradation of 53BP1 
by the cysteine protease cathepsin L (CTSL), which translocates 
into the nucleus in lamins-deficient cells.26,27 Accordingly, deple-
tion or inhibition of CTSL activity rescued the levels of 53BP1, as 
well as the defects in NHEJ and the genomic instability observed 
in lamins-deficient cells.28,29 Most recently, we found that CTSL-
mediated degradation of 53BP1 is activated upon depletion of 
BRCA1 in breast cancer cells, which allows BRCA1-deficient 
cells to rescue HR and overcome genomic instability and growth 
arrest.30 Interestingly, inhibition of CTSL stabilized 53BP1 pro-
tein in the context of BRCA1 deficiency and increased the sen-
sitivity of BRCA1-deficient cells to DNA damaging strategies. 
Importantly, we also found an inverse linear correlation between 
nuclear levels of CTSL and 53BP1 in breast tumors from patients 
with sporadic TNBC and patients carrying germline mutations 
in the BRCA1 gene. Altogether, these studies demonstrate a key 
role for CTSL in the regulation of 53BP1 protein levels, thus 
supporting the notion that inhibition of CTSL-mediated deg-
radation of 53BP1 could represent a new therapeutic strategy for 
breast cancers with the poorest prognosis, as well as some lamin-
related diseases.
Despite these recent findings, many questions still remain 
about the regulation of 53BP1 levels and the functional relation-
ship between 53BP1 and BRCA1 during the cell cycle. In addi-
tion, the regulation of these proteins in the many cells in the 
body that are not cycling remains obscure. Here, we monitored 
the regulation of 53BP1 levels during exit and re-entry into the 
cell cycle. We find changes in global levels of 53BP1 protein dur-
ing growth arrest that mirror BRCA1 expression, and that are 
regulated by CTSL. Importantly, our study reveals profound dif-
ferences in the regulation of BRCA1 and 53BP1 proteins between 
cycling and non-cycling cells.
Results
Inverse correlation between CTSL and levels of 53BP1 and 
BRCA1 proteins in growth-arrested human fibroblasts
Previous studies showed that BRCA1 expression increases as 
cells progress through the G
1
 phase of the cell cycle, peak dur-
ing S phase, and remain elevated at the G
2
/M transition.15-17 In 
contrast, a recent study showed that the levels of BRCA1 do not 
change during the cell cycle.20 Thus, whether or not BRCA1 
levels are regulated during the cell cycle remains controversial. 
Similarly, how the levels of 53BP1 are regulated during the cell 
cycle or during growth arrest is not known. Given our previous 
finding that CTSL regulates 53BP1 stability,27-29 we investigated a 
possible relationship between CTSL and 53BP1 levels in growth-
arrested and cycling cells by using human fibroblasts immortal-
ized with telomerase (BJ + hTert), which have intact cell cycle 
regulation and growth arrest by contact inhibition. BJ + hTert 
fibroblasts were plated at high confluency and maintained con-
fluent for 72 h to induce growth arrest. At this point, cells were 
either collected, or replated at low density to allow re-entry into 
the cell cycle. Samples of cells were collected at different times 
after re-entry into the cell cycle. We monitored the cell cycle dis-
tribution profile at each condition via propidium iodide content. 
As shown in Figure 1A, asynchronously growing cells show a 










, we monitored the presence of Ki67, a marker that is 
absent in cells arrested in G
0
. As shown in Figure S1, most of the 
cells arrested by confluency are positive for Ki67, indicating that 
cells arrest primarily in G
1
. Figure 1A also shows that approxi-
mately 24 h after re-plating, cells had re-entered the cell cycle and 
showed a normal cell cycle distribution profile.
Next, we monitored the levels of BRCA1, CTSL, and 53BP1 
during growth arrest and at different times after re-entry into 
the cell cycle and compared the levels of these proteins to those 
of asynchronously growing cells (Fig. 1B, left panels). Arrest in 
G
1
 is accompanied by a profound increase in the levels of CTSL 
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growing cells. We also observed decreased BRCA1 levels in 
growth-arrested cells, confirming previous results. As cells 
re-entered the cell cycle, a reduction in CTSL correlated with 
increased 53BP1 and BRCA1 protein levels. Consistent with 
the decrease in CTSL levels upon re-entry into the cell cycle, 
cathepsin L activity was reduced as early as 16 h post-release 
from growth arrest (Fig. S2). In contrast, we found that the lev-
els of the single-strand DNA-binding protein RPA remain con-
stant during exit and re-entry into the cell cycle. In addition, 
we show that the Rb family member p107 also mirror 53BP1 
and BRCA1 expression, with low levels in growth-arrested cells, 
which increase as cells re-enter the cell cycle. Changes in the 
levels of Cyclin A throughout the course of the experiment were 
monitored as an additional indicator of cell cycle progression, as 
Cyclin A is markedly reduced in G
1
 phase. We monitored levels of 
A-type lamins (Lamin A/C) as loading control. The data demon-
strate that 53BP1 protein levels fluctuate during exit and re-entry 
into the cell cycle, mirroring the levels of BRCA1, and that CTSL 
inversely correlates with the levels of both proteins.
To determine whether CTSL contributes to 53BP1 downreg-
ulation in growth-arrested cells, we inhibited CTSL activity in 
BJ + hTert fibroblasts via treatment with the cathepsin inhibitor 
E64 (10 μM) throughout the time course of the experiment. As 
shown in Figure 1C, treatment with E64 did not modify the 
Figure 1. Differences in the levels of DNA repair factors between growth-arrested and cycling human fibroblasts. (A) Cell cycle profile of human fibro-
blasts expressing telomerase (BJ + hteRt) either growing asynchronously, growth arrested by contact inhibition, or released from the growth arrest. 
Cells were fixed and labeled with propidium iodide and analyzed for fluorescent DNA content using the Nexcelom Cellometer. the percentage of cells in 
G0/G1, S, and G2/M phases of the cell cycle is shown under each cell cycle profile. (B) Western blots to monitor the levels of the protease cathepsin L (CtSL), 
DNA repair factors (53Bp1, BRCA1, RpA), cell cycle regulators (Cyclin A, p107), and loading control Lamin A/C in growth-arrested and cycling fibroblasts 
treated with cathepsin inhibitor e64 or vehicle control. Note the marked increase in CtSL and the decrease in 53Bp1 and BRCA1 levels in growth-arrested 
cells and how e64 treatment prevents 53Bp1 decrease. (C) Cell cycle profile monitored as in (A) but in cells incubated with 10 μM e64 throughout the 
time course of the experiment. (D) Western blots in cells treated with e64 to monitor the same proteins as in (B). Note how inhibition of cathepsin activity 
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cell cycle profile at any of the conditions tested. Interestingly, 
we found that E64 treatment prevented the decrease of 53BP1 in 
contact-inhibited cells (Fig. 1B, right panels). In contrast, E64 
had no effect on the levels of 53BP1 or any of the other proteins 
tested in asynchronously growing cells or in cells that re-entered 
the cell cycle. These results indicate that CTSL participates in 
the regulation of 53BP1 levels specifically in fibroblasts arrested 
in G
1
 by contact inhibition.
Transcriptional regulation of CTSL, 53BP1, and BRCA1 in 
growth-arrested fibroblasts
The above results show profound changes in the levels of 
CTSL, 53BP1, and BRCA1 proteins during exit and re-entry into 
the cell cycle and demonstrate a role for CTSL in the regulation of 
53BP1 levels. Here, we determined whether any of these changes 
are due to transcriptional regulation of the genes. We performed 
qRT-PCR in BJ + hTert fibroblasts growing asynchronously, 
growth arrested by contact inhibition, or allowed to re-enter the 
cell cycle. We compared the levels of CTSL, 53BP1, and BRCA1 
transcripts between cells treated with vehicle control (H
2
O), or 
with E64 to inhibit cathepsin activity. As shown in Figure 2A, 
the levels of BRCA1 transcripts are markedly decreased in con-
tact-inhibited cells and progressively increase as cells re-enter 
the cell cycle, consistent with previous reports. Importantly, we 
found that the levels of BRCA1 transcripts are not affected by 
inhibition of CTSL activity at any condition tested. In contrast, 
we observed a significant upregulation of CTSL transcripts in 
growth-arrested cells (Fig. 2B). Treatment with E64 did not have 
a profound effect in the levels of CTSL transcripts throughout 
the time course of the experiment. Thus, the levels of BRCA1 
and CTSL transcripts correlate with proteins levels, indicat-
ing that both proteins are regulated transcriptionally during 
growth arrest. Interestingly, we found that the levels of 53BP1 
transcripts remain constant upon contact inhibition (Fig. 2C), 
despite the marked decrease in 53BP1 protein (Fig. 1B, left pan-
els). Furthermore, treatment with E64 does not alter the levels 
of 53BP1 transcripts during growth arrest, although it stabilizes 
the levels of 53BP1 protein (Fig. 1B, right panels). These results 
indicate that 53BP1 protein stability is regulated during growth 
arrest, and that CTSL plays a major role in the degradation of 
53BP1. Intriguingly, we also found that inhibition of CTSL by 
E64 treatment results in a consistent downregulation of 53BP1 
transcripts levels as cells re-enter the cell cycle. However, these 
changes in transcription do not translate into decreased 53BP1 
protein levels. These results suggest that CTSL impacts on 53BP1 
expression at different levels. On one hand, CTSL activity medi-
ates degradation of 53BP1 protein in growth-arrested cells while 
maintaining 53BP1 transcripts levels in cycling cells.
Formation of 53BP1 and BRCA1 IRIF in growth-arrested 
and cycling fibroblasts
The decrease in global levels of 53BP1 and BRCA1 shown 
above suggests that growth-arrested fibroblasts could be compro-
mised in their ability to accumulate these DNA repair factors 
at sites of DNA damage. To test this hypothesis, we performed 
immunofluorescence (IF) with 53BP1 and BRCA1 antibodies in 
cells contact-inhibited and cells growing asynchronously that are 
irradiated with 8 Gy or mock irradiated. Upon irradiation, 53BP1 
and BRCA1 proteins are recruited to sites of DNA damage, 
forming ionizing radiation-induced foci (IRIF). Figure 3A shows 
representative images of BRCA1 content in growth-arrested and 
asynchronous fibroblasts in the absence of ionizing radiation. In 
growth-arrested cells, BRCA1-positive cells are rarely observed. 
In contrast, cells positive for BRCA1 are readily observed in asyn-
chronously growing cells, as expected. Interestingly, the few cells 
Figure 2. transcripts levels of BRCA1, CtSL, and 53Bp1 in growth-arrested 
and cycling human fibroblasts. (A) Quantitation of BRCA1 transcripts lev-
els by qRt-pCR in human fibroblasts expressing telomerase (BJ + hteRt) 
either growing asynchronously, growth arrested by contact inhibition, 
or released from the growth arrest. Relative expression is compared in all 
conditions between cells incubated in water as control and cells incubated 
with 10 μM e64. (B) Quantitation of CtSL transcripts levels as in (A). (C) 
Quantitation of 53Bp1 transcripts levels as in (A). **Represents P value of 
statistical significance (P ≤ 0.05) of that sample compared with all the other 
samples in the experiment. the complete statistical analysis of all the sam-
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positive for BRCA1 consistently showed higher label intensity 
with DAPI, indicating that these cells have higher DNA content, 
thus representing a post-replication stage of the cell cycle (S or G
2
 
phases). The graph in Figure 3A shows the quantitation of global 
BRCA1 fluorescence intensity in asynchronous and growth-
arrested cells. We found a statistically significant decrease in 
BRCA1 intensity in arrested cells. Next, we compared the for-
mation of BRCA1 IRIF between growth-arrested and asynchro-
nously growing cells (Fig. 3B). We found that a high percentage 
of asynchronously growing cells present with BRCA1 IRIF. In 
contrast, only a few growth-arrrested cells present with BRCA1 
IRIF, consistent with the global decrease of BRCA1 protein levels 
Figure 3. Levels of BRCA1 and 53Bp1 and formation of IRIF in growth-arrested and cycling cells. (A) Immunofluorescence with BRCA1 antibody was per-
formed in asynchronous and contact-inhibited cells that were mock irradiated. DApI staining was used to identify all nuclei. Graph shows quantitation 
of the intensity of fluorescence (relative fluorescence units) in 200 cells per condition. (B) IF with BRCA1 antibody in cells of the same growth conditions 
as (A) after irradiation with 8 Gy. Note the decrease in BRCA1 intensity of fluorescence, both in control and irradiated growth-arrested cells. (C) the same 
experiments as in (A) were performed with 53Bp1 antibody. (D) the same experiments as in (B) were performed with 53Bp1 antibody. Note how 53Bp1 
levels mirror BRCA1 in all conditions tested, with low levels of 53Bp1 in growth-arrested cells irradiated and control. *Represents P value of statistical 
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in these cells. As a consequence, the global intensity of BRCA1 
fluorescence is markedly decreased in irradiated arrested fibro-
blasts. Thus, non-cycling fibroblasts are unable to form BRCA1 
foci after IR.
In addition, we compared the content of 53BP1 between 
growth-arrested and asynchronously growing fibroblasts by IF in 
the absence of IR. As shown in Figure 3C, growth-arrested fibro-
blasts show a marked decrease in the intensity of labeling with 
53BP1 antibody, consistent with the decrease in the global levels 
of the protein. Similarly, we found a striking difference in the 
intensity of 53BP1 IRIF between growth-arrested and asynchro-
nously growing cells (Fig. 3D). We confirmed the specificity of 
the antibody by performing immunofluorescence and immuno-
histochemistry in cells depleted of 53BP1 via lentiviral transduc-
tion with shRNA (Fig. S3). Overall, the data demonstrate that 
non-cycling cells do not accumulate 53BP1 at DNA repair foci.
Next, we tested whether activation of CTSL-mediated deg-
radation of 53BP1 is specific of G
1
-arrested cells, or if it is also a 
characteristic of the G
1
 phase in cycling cells. We took advantage 
of the fact that cyclin A is absent in this phase of the cell cycle. 
Thus, we performed dual immunofluorescence with cyclin A and 
53BP1 antibodies in asynchronous cells control or irradiated with 
8 Gy. As shown in Figure 4, cells positive and negative for cyclin 
A present with similar global levels of 53BP1. In addition, cells 
in the G
1
 phase of the cell cycle (cyclin A-negative) were able to 
form 53BP1 IRIF with the same intensity as cells in S/G
2
 phases 
of the cell cycle (cyclin A-positive), as assessed by quantitation 
of intensity of fluorescence (graph). These results are consistent 
with previous studies showing that 53BP1 IRIF can form in 
all phases of the cell cycle.19,20,31 However, one study in hTert-
immortalized retinal pigment epithelial cells (RPE1), showed 
expression of 53BP1 in cells growth 
arrested by serum deprivation.32 This 
discrepancy suggests that different cell 
lines might regulate 53BP1 in a dis-
tinct manner. Whether or not growth-
arrested hTert-RPE1 cells can activate 
CTSL remains unknown. Overall, our 
data demonstrate profound differences 
in the regulation of 53BP1 between 
cycling and non-cycling human fibro-
blasts. Non-cycling fibroblasts acti-
vate CTSL-mediated degradation of 
53BP1, while cycling fibroblasts main-
tain constant levels of 53BP1 through-
out the cell cycle.
Inverse correlation between CTSL 
and levels of 53BP1 and BRCA1 pro-
teins in serum-starved MCF7 cells
Our results indicate that BJ + hTert 
fibroblasts growth arrested in G
1
 
by contact inhibition transcription-
ally downregulate BRCA1 and acti-
vate CTSL-mediated degradation 
of 53BP1. Our previous studies had 
shown that breast cancer cells (MCF7) 
growth arrested by serum deprivation exhibit high levels of 
CTSL and low levels of BRCA1 and 53BP1.30 Here, we deter-
mined whether CTSL is responsible for the decrease of 53BP1 in 
these cells. MCF7 cells were lentivirally transduced with shRNA 
specific for depletion of CTSL (shCTSL) or shRNA control 
(shscr). Both cell lines were grown in complete media or media 
with 0.1% serum (starved) for 48 h and either collected imme-
diately, or re-plated in complete media containing 10% serum 
to allow re-entry into the cell cycle. Figure 5A shows the cell 
cycle profile of cells subjected to the different treatments assessed 
by propidium iodide staining. Serum deprivation led to growth 
arrest of MCF7 cells, and approximately 24 h post-release, cells 
exhibit a normal cell cycle profile. Subsequently, we monitored 
the levels of 53BP1, BRCA1, and CTSL proteins through-
out the time course of the experiment. As shown in Figure 5B 
(left panels), growth arrest by serum starvation of MCF7 cells 
proficient in CTSL leads to a marked decrease in the levels of 
BRCA1 and 53BP1 proteins, concomitant with an increase in 
CTSL protein, as previously reported.30 In addition, an increase 
in 53BP1 and BRCA1 protein levels are observed upon re-entry 
of MCF7 cells into the cell cycle. Thus, exit and re-entry into the 
cell cycle of MCF7 cells recapitulates the phenotype observed 
in BJ + hTert fibroblasts, indicating that this is a phenomenon 
induced by different types of growth arrest and in different cell 
types. Interestingly, we find that depletion of CTSL prevents the 
decrease of 53BP1 in serum-starved MCF7 cells (Fig. 5B, right 
panels), indicating that CTSL is responsible for the decrease in 
53BP1 protein in this context. Importantly, depletion of CTSL 
does not affect the cell cycle profile at any of the conditions tested 
(Fig. 5C). In contrast, the levels of BRCA1 were unaffected by 
the loss of CTSL, showing a decrease in growth-arrested cells. 
Figure 4. Levels of 53Bp1 and formation of IRIF in cycling cells. Immunofluorescence with 53Bp1 and 
Cyclin A antibodies was performed in asynchronously growing cells that were irradiated with 8 Gy or 
mock irradiated. DApI staining was used to identify all nuclei. Cyclin A positive cells represent cells in S/
G2 phases of the cell cycle, while Cyclin A-negative cells represent cells in G1. Graphs show quantitation 
of the intensity of fluorescence (relative fluorescence units) in 200 cells per condition. We compared 
intensity of fluorescence of 53Bp1 between Cyclin A-positive (S/G2) and Cyclin A-negative (G1) cells that 
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Consistent with observations in BJ + hTert fibroblasts, the levels 
of RPA were constant throughout the cell cycle, and the levels of 
Cyclin A and p107 were downregulated in growth-arrested cells. 
Altogether, our results demonstrate that CTSL plays a role in the 
regulation of 53BP1 protein levels in growth-arrested cells, allow-
ing 53BP1 protein levels to mirror levels of BRCA1 throughout 
the cell cycle.
Transcriptional regulation of CTSL, 53BP1, and BRCA1 
during growth arrest in MCF7 cells
Here, we determined whether the changes in CTSL, 53BP1, 
and BRCA1 protein levels observed in MCF7 cells during the cell 
cycle correlate with levels of transcription of the corresponding 
genes. We also compared transcripts levels between MCF7 cells 
proficient and deficient in CTSL. We performed qRT-PCR in 
MCF7 cells growing asynchronously, cells growth arrested by 
serum starvation, and cells that re-entered the cell cycle. As shown 
in Figure 6A, serum starvation leads to a statistically significant 
downregulation of BRCA1 transcripts levels, consistent with the 
decrease in BRCA1 protein, and recapitulating the phenotype of 
fibroblasts growth arrested by contact inhibition. In addition, 
we found an upregulation of BRCA1 transcripts as MCF7 cells 
re-entered the cell cycle, also consistent with the results in fibro-
blasts. Importantly, depletion of CTSL did not affect the levels 
of BRCA1 transcripts at any of the conditions tested, indicating 
Figure 5. Differences in the levels of DNA repair factors between growth-arrested and cycling breast cancer cells. (A) Cell cycle profile of breast cancer 
cells (MCF7) either growing asynchronously, growth arrested by serum deprivation (starved), or released from the growth arrest by serum supplementa-
tion. Cells were fixed and labeled with propidium iodide and analyzed for fluorescent DNA content using the Nexcelom Cellometer. the percentage of 
cells in G0/G1, S, and G2/M phases of the cell cycle is shown under each cell cycle profile. (B) Western blots to monitor the levels of the protease cathep-
sin L (CtSL), DNA repair factors (53Bp1, BRCA1, and RpA), and cell cycle regulators (Cyclin A, p107) in MCF7 cells proficient or deficient in CtSL (shscr 
and shCtSL, respectively). Note the increase in CtSL and the marked decrease in 53Bp1 and BRCA1 levels in growth-arrested cells. (C) Cell cycle profile 
monitored as in (A), but in MCF7 cells depleted of CtSL via lentiviral transduction with a specific shRNA (shCtSL). the blots shown in (B) represent the 
same experiment and thus levels of all proteins can be compared. Note how depletion of cathepsin L prevents the decrease in 53Bp1 protein levels. 
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that CTSL does not impact on BRCA1 expression during the 
cell cycle. In Figure 6B we show the marked depletion of CTSL 
transcripts achieved by transduction with the specific shRNA. 
Importantly, serum starvation leads to upregulation of CTSL 
transcripts, which are downregulated upon re-entry of the cells 
into the cell cycle. This is also consistent with the results obtained 
in fibroblasts. Lastly, we find that growth arrest of MCF7 cells 
by serum starvation does not alter the levels of 53BP1 transcripts 
despite the marked downregulation of 53BP1 protein. These 
results are consistent with activation of CTSL-mediated degrada-
tion of 53BP1 protein upon growth arrest in different cell lines 
and by different means. Importantly, treatment of MCF7 cells 
with hydroxyurea (HU) to inhibit DNA replication and arrest 
cells in S phase does not lead to downregulation of BRCA1 or 
activation of CTSL-mediated degradation of 53BP1 (Fig. 6D). 
Rather, increased levels of 53BP1 and BRCA1 proteins are 
observed in HU-treated MCF7 cells. These results suggest that 
the decrease of 53BP1 and BRCA1 proteins is specific to growth 
arrest prior to replication.
Discussion
There is substantial evidence that NHEJ is active in all 
phases of the cell cycle, while HR is particularly important in S/
G
2
 phases.12 Some studies have shown that BRCA1 levels fluc-
tuate during the cell cycle and markedly increase during S/G
2
 
phases,16,17 while others have reported constant levels of BRCA1 
during the cell cycle.20 Recent elegant studies in asynchronously 
growing cells proposed the notion of a cell cycle-regulated cir-
cuit, whereby the recruitment of BRCA1/CtIP or 53BP1/Rif1 
complexes regulate the choice of DNA DSB repair pathway 
during the cell cycle.20 In this model, the choice of mechanism 
of DNA repair is regulated by recruitment, not by changes in 
the levels of the proteins/complexes in cycling cells. The pres-
ent study investigated whether a similar functional relationship 
exists in non-cycling cells, which is a state of many cells in the 
body that are not dividing, but that are poised to respond to 
proliferation stimuli. We find profound differences in the regu-
lation of 53BP1 and BRCA1 between cycling and non-cycling 
cells. Growth-arrested cells exhibit a marked downregulation of 
BRCA1 transcripts and protein levels as well as upregulation of 
CTSL and activation of CTSL-mediated degradation of 53BP1. 
Importantly, cells that are allowed to re-enter the cell cycle revert 
to a cycling phenotype, with upregulation of BRCA1 and cessa-
tion of CTSL-mediated degradation of 53BP1. These results sug-
gest that BRCA1 and 53BP1 play an important role in replicating 
cells, but seem to be dispensable in non-dividing cells.
An important question is why growth-arrested cells activate 
CTSL-mediated degradation of 53BP1. Based on previous stud-
ies showing that 53BP1 plays a major role in the genomic insta-
bility that characterizes BRCA1-deficient cells,1-5 it is tempting 
to speculate that a scenario in which BRCA1 is downregulated, 
keeping high levels of 53BP1, would be detrimental for the cells. 
Figure 6. transcripts levels of BRCA1, CtSL, and 53Bp1 in growth-arrested 
and cycling breast cancer cells. (A) Quantitation of BRCA1 transcripts lev-
els by qRt-pCR in breast cancer cells (MCF7) either growing asynchro-
nously, growth arrested by serum deprivation (starved), or released from 
the growth arrest by serum supplementation. Relative expression is 
compared in all conditions between CtSL-proficient (shSCR) and CtSL-
deficient (shCtSL) cells. (B) Quantitation of CtSL transcripts levels as in 
(A). (C) Quantitation of 53Bp1 transcripts levels as in (A). **Represents 
P value of statistical significance (P ≤ 0.05) of that sample compared 
with all the other samples in the experiment. the complete statistical 
analysis of all the samples under the different conditions is shown in 
supplemental information. (D) MCF7 cells growing asynchronously were 
incubated in the presence of hydroxyurea (HU 1mM) or vehicle control 
(H2o) overnight and processed for western blot to monitor the levels of 
CtSL, 53Bp1, and BRCA1. Note how HU treatment slightly increases the 
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In fact, MCF7 cells deficient in both BRCA1 and 53BP1 do not 
present profound genomic instability.30 However, stabilization 
of 53BP1 in BRCA1-deficient cells induces a marked increase in 
genomic instability in response to IR or treatment with PARP 
inhibitors. These studies suggest that a balance between BRCA1 
and 53BP1 is essential for the maintenance of genomic stability. 
As such, maintenance of 53BP1 levels in the context of BRCA1 
deficiency, or maintenance of BRCA1 levels in the context of 
53BP1 deficiency are associated with defects in DNA repair, 
genomic instability, and increased cancer incidence.21-25
We envision that a sensor mechanism could potentially acti-
vate CTSL-mediated degradation of 53BP1 to mirror the low 
levels of BRCA1 in non-cycling cells. Once BRCA1 is upregu-
lated by re-entry into the cell cycle, cells stabilize 53BP1 protein 
levels. Thus, it is possible that the downregulation of BRCA1 in 
non-cycling cells is triggering the activation of CTSL-mediated 
degradation of 53BP1. Although we do not know the nature 
of such a “sensing” mechanism, this scenario resembles other 
observations made by us in cells subjected to different stresses. 
For example, we previously found that depletion of BRCA1 
in breast cancer cells activates CTSL-mediated degradation of 
53BP1, which, in turn, allows these cells to overcome genomic 
instability and growth arrest.30 In addition, we demonstrated 
that CTSL-mediated degradation of 53BP1 is also activated 
upon depletion of the structural nuclear proteins A-type lam-
ins.28 Interestingly, lamins-deficient cells also downregulate 
BRCA1 transcripts and protein levels, thus providing another 
scenario in which loss of BRCA1 coincides with degradation of 
53BP1 by CTSL.29 Other reports have also shown activation of 
CTSL as well as its accumulation in the nucleus in response to 
expression of oncogenic Ras, although the degradation of 53BP1 
in this context was not tested.33,34 Intriguingly, expression of Ras 
inactivates the BRCA1 DNA repair function by dissociating 
BRCA1 from chromatin.35
Altogether, the data suggests that this 53BP1 degradation 
mechanism is activated under different stress conditions, and 
that in many cases the process is associated with loss of BRCA1 
function. Elucidating the molecular mechanisms responsible for 
activating CTSL-mediated degradation of 53BP1 could reveal 
new information linking this process with the loss of BRCA1 
function. We envision that future studies need to address whether 
cancer-related mutations in BRCA1 activate this degradation 
pathway,36 which could have important consequences for tumori-
genesis. Furthermore, given that levels of 53BP1 have been linked 
to increased species lifespan,37 understanding the regulation of 
53BP1 levels will be relevant for aging. Overall, our findings sup-
port an important role for CTSL not only in the regulation of 
53BP1 stability in tumor cells, but also as a regulator of protein 
stability during growth arrest in both normal and tumor cells. 
In addition, our studies identify CTSL-mediated degradation 
of 53BP1 as a mechanism activated in non-cycling cells, which 
interestingly is exploited by BRCA1-deficient tumor cells to 
reduce genomic instability and ensure proliferation and viabil-
ity.30 Furthermore, levels of CTSL inversely correlate with levels 
of 53BP1 in breast cancers with the poorest prognosis, such as 
triple-negative and BRCA1-mutated. Therefore, this mechanism 
of 53BP1 loss provides a new target for the development of thera-
peutic strategies for specific types of cancers.
Materials and Methods
Cell culture
Human fibroblasts expressing telomerase (BJ + hTERT) and 
MCF7 cells were maintained in DMEM supplemented with 10% 
FBS, antibiotics, and antimycotics (complete media).
E64 treatment
Cells were incubated with the broad-spectrum cathepsin 
inhibitor E-64 (E3132, Sigma-Aldrich) diluted in H
2
O at a con-
centration of 10 µM for the whole duration of the experiments.
Ionizing radiation
For assaying IRIF formation, cells were irradiated with 
8 Gy and fixed and processed for immunofluorescence 1 h 
post-irradiation.
Contact inhibition of fibroblasts
Eight × 106 BJ + hTERT fibroblasts were plated in 100-mM 
tissue culture (TC) dishes in complete media. Cells were main-
tained confluent for 72 h prior to being collected as “contact 
inhibited” or plated in complete media at 1 × 106 cells in 100 mM 
TC dishes to allow re-entry into the cell cycle. For time point col-
lection, all media, washes, and trypsinized cells were collected by 
centrifugation for analysis.
Serum starvation of MCF7 cells
MCF7 cells were plated in DMEM containing 0.1% FBS, 
antibiotics and antimycotics (starvation media) and maintained 
in this media for 48 h prior to being collected as “serum starved” 
or media being refreshed with FBS to a final concentration of 
10% to allow re-entry into the cell cycle. For time point collec-
tion, all media, washes and trypsinized cells were collected by 
centrifugation for analysis.
Immunoblotting
Cells were lysed in RIPA buffer (150 mM NaCl, 50 mM 
Tris-HCl pH 7.4, 1% NP-40, 0.2% SDS, 0.25% sodium deoxy-
cholate, and 1 mM EDTA) supplemented with HALT protease 
and phosphatase inhibitor cocktail (Thermo Pierce). Lysates 
were sheared using 10 passes through a 26-gauge needle fol-
lowed by 10 passes through a 30-gauge needle and sonication for 
7 min. Protein concentration was determined using the BioRad 
Dc Protein Assay, and 60–80 μg of total protein was separated 
by SDS-PAGE on a 4–15% Criterion TGX Gel (Bio-Rad) and 
transferred to a nitrocellulose membrane using the Trans-Blot 
Turbo system (Bio-Rad). Antibodies used include: Lamin A/C 
(sc-20681, SCBT); 53BP1 (H-300: sc-22760, SCBT); RAD51 
(H-92: sc-8349, SCBT); BRCA1 (D-9: sc-6954, SCBT); CTSL 
(C1391, Leinco); p107 (C-18: sc-318, SCBT); RPA (NA18, 
Millipore); and Cyclin A (sc-271682, SCBT); donkey anti-
rabbit HRP-secondary antibody (ab16284, Abcam); bovine 
anti-goat HRP-secondary antibody (sc-2352, SCBT); goat anti-
mouse HRP-secondary antibody (31430, Thermo Scientific). 
Nitrocellulose membranes were blocked using 3% milk pre-
pared in PBS + 0.1% Tween-20. Antibodies were diluted in 3% 
milk prepared in PBS + 0.1% Tween-20, and membranes were 
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and secondary antibody incubations. Membranes were developed 
using Thermo Pierce ECL (Fisher).
Immunofluorescence
Cells growing on coverslips were processed directly for IF, 
or irradiated with 8 Gy and processed 1 h post-irradiation for 
53BP1, or 4 h post-irradiation for BRCA1. For immunofluores-
cence of 53BP1, cells were fixed in 3.7% formaldehyde + 0.2% 
Triton-X 100 in PBS for 10 min at RT, and blocked for 1 h at 
37 °C in 2% BSA/0.1% Triton-X100 in PBS. Incubations with 
53BP1 antibody (1:1000, NB100–304, Novus) and Alexa Fluor 
488 goat anti-rabbit (1:1000, A11008, Invitrogen) secondary 
antibody were performed for 1 h at 37 °C. Washes were per-
formed in PBS and slides were counterstained with DAPI in 
Vectashield (H-1200, Vector Labs). Microscopy and photo cap-
ture was performed on a Leica DM5000 B microscope using 63× 
or 100× oil objective lenses (NA 1.4 and 1.3, respectively) with a 
Leica DFC350FX digital camera and the Leica Application Suite 
(Version 4.1.0).
BRCA1 immunofluorescence was performed following a pro-
tocol from the Fernandez–Capetillo laboratory. Briefly, cells were 
washed twice with PBS, and incubated in CSK I buffer (10 mM 
PIPES pH6.8, 100 mM NaCl, 300 mM sucrose, 3 mM MgCl
2
, 
1 mM EGTA, and 0.5% Triton X-100) for 5 min. Coverslips 
were washed 5 times with cold PBS and fixed in modified STF 
buffer (150 mM 2-Bromo-2-nitro-1,3-propanediol, 108 mM dia-
zolidinyl urea, 10 mM Na citrate, and 50 nM EDTA pH 5.7) 
for 30 min at RT. Coverslips were then washed twice with cold 
PBS and permeabilized (PB buffer: 100 mM Tris-HCl pH 7.4, 50 
mM EDTA pH 8.0, and 0.5% Triton X-100) for 15 min at room 
temperature followed by 2 washes in PBS. Blocking, antibody 
staining, and mounting were performed as described above, with 
BRCA1 antibody (sc-6954, Santa Cruz) diluted at 1:200 and 
Alexa Fluor 594 goat anti-mouse secondary antibody (A11005, 
Invitrogen) diluted at 1:1000.
Fluorescence intensity was measured using ImageJ. 
Measurements were taken individually for each cell, as well as for 
a small adjacent area to account for background. The corrected 
total cell fluorescence (CTCF) was obtained by subtracting the 
product of the cell’s area and the mean fluorescence of the back-
ground, from the integrated density of the target cell, following 
the equation: CTSF = integrated density – (mean background 
fluorescence × area of cell).
Analysis of cell cycle profile
Cells were collected from asynchronous culture, contact-
inhibited culture (fibroblasts), serum-starved culture (MCF7), 
or after re-entry into the cell cycle at various time points. Cell 
pellets were washed with PBS once and suspended in 500 μl PBS 
prior to the dropwise addition of 4.5 ml ice-cold 70% ethanol 
while being vortexed at 600 rpm to fix. The cell suspension was 
stored at 4 °C until analysis. Fixed cells were pelleted at 1000 × 
g, washed with PBS, and suspended in 1 ml propidium iodide 
staining solution (400 μg /ml). Cells were incubated in the stain-
ing solution for 15 min at 37 °C. Stained cells were analyzed for 
fluorescent DNA content using the Nexcelom Cellometer Vision 
CBL, and cell cycle profiles were created by the program Fcs 
Express 4 Research Edition.
Quantitative reverse-transcription PCR
RNA was purified from cell pellets using the Bio-Rad Aurum 
Kit. cDNA was generated by reverse transcription of 750 ng total 
RNA using Bio-Rad iScript. qRT-PCR was performed using the 
7900HT Fast Real-Time PCR system (Applied Biosystems) with 
the Taqman® Universal PCR Master Mix and Taqman® probe 
assays targeting HsBRCA1 (Hs01556193_m1), HsTP53BP1 
(Hs00996818_m1), HsCTSL (Hs00377632_m1), and HsPPIB 
(Hs00168719_m1) according to the manufacturer’s directions. 
Reactions were performed in triplicate and target gene and 
endogenous controls were amplified in the same plate. Relative 
quantitative measurements of target genes were determined by 
using ΔCt calculations.
Viral transduction
Lentiviral transductions were performed as described.27 Briefly, 
293T cells were transfected with viral packaging (pHR’8.2ΔR) 
and envelope plasmids (p-CMV-VSV-G) along with the vector 
containing the shRNA of interest (shscramble or shSCR and 
shCTSL). After 48 h, virus-containing media was harvested 
to infect target cells (MCF7). Following a 4 h infection, cells 
were allowed to recover for 48 h and selected with puromycin. 
Viral envelope and packaging plasmids were gifts from Sheila 
Stewart (Washington University). shRNAs were obtained from 
Sigma-Aldrich.
Cathepsin L activity
Cathepsin L and total Cathepsin activity was measured by using 
the fluorogenic substrate Z-Phe-Arg-AMC from the InnoZyme™ 
Cathepsin L Activity Kit (EMD Chemicals) following the manu-
facturer’s instructions. Briefly, 106 cells were lysed in Lysis Buffer 
(400 mM Na phosphate buffer pH 6, 75 mM NaCl, 4 mM EDTA, 
0.25% Triton X-100). One hundred µg of protein extract were 
used per sample. Samples were measured in duplicate. Cleaved 
Z-Phe-Arg-AMC substrate was detected by fluorescence emission 
(Exc. max: 360 nm; Emi. max: 460 nm). Cathepsin L activity 
was determined in the presence of CA 074, a specific Cathepsin B 
inhibitor. As a negative control, the Cathepsin L inhibitor Z-FY(t-
but)-DMK was used. Total cysteine activity was determined as the 
cleavage of the substrate in the absence of inhibitors.
Statistical analysis
For all the experiments, a “2-tailed” Student t test was used 
to calculate statistical significance of the observed differences. 
Microsoft Excel v.2010 was used for the calculations. In all cases, 
differences were considered statistically significant when P < 
0.05. For some figures the 95% confidence interval based on an 
exact binomial distribution was calculated to determine signifi-
cant differences among samples.
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